病例报告

眼睑Merkel细胞癌2例

Eyelid Merkel cell carcinoma: 2 case reports

:744-749
 
Merkel细胞癌(Merkel cell carcinoma,MCC)是一种少见的高度恶性的皮肤原发性神经内分泌癌,发生于眼睑的MCC更加罕见。本文对2例眼睑MCC患者的临床病史和治疗过程进行回顾和总结。1例初发患者经手术彻底切除,效果良好,随访7年,未再复发;1例患者在外院切除术后2个月,于眼睑原位复发,再次行手术彻底切除,2个月后同侧腮腺淋巴结及颈前淋巴结扩散,目前仍在肿瘤科进一步放化疗中。复习相关文献并结合本组病例提示,MCC诊断主要依靠病理检查,彻底切除病灶并结合术后放化疗是其治疗的主要手段,免疫治疗是目前新的发展趋势。
The Merkel cell carcinoma (MCC) is a rare highly malignant primary neuroendocrine carcinoma of the skin,especially in the eyelids. In this report, the clinical history and treatment course of 2 patients with MCC of the eyelid were reviewed and summarized. Patient 1 with primary MCC of eyelid was treated with complete surgical excision, with good results. Follow-up for 7 years had shown no recurrence. Patient 2 with the eyelid relapse in situ two months after resection in another hospital, was treated with complete surgical excision again, but the tumor metastasized to the ipsilateral lymphonodi parotidici and cervical lymph nodes two months after the surgery. The patient is now going through radiotherapy and chemotherapy in oncology department. According to the review of literatures, the diagnosis was based on the pathologic evidence. Complete removal of lesion combined with postoperative radiotherapy and chemotherapy is a major means of treatment for MCC. Immunotherapy will play a more important role in the future.
病例报告

眼睑Merkel细胞癌2例

Eyelid Merkel cell carcinoma: 2 case reports

:744-749
 
Merkel细胞癌(Merkel cell carcinoma,MCC)是一种少见的高度恶性的皮肤原发性神经内分泌癌,发生于眼睑的MCC更加罕见。本文对2例眼睑MCC患者的临床病史和治疗过程进行回顾和总结。1例初发患者经手术彻底切除,效果良好,随访7年,未再复发;1例患者在外院切除术后2个月,于眼睑原位复发,再次行手术彻底切除,2个月后同侧腮腺淋巴结及颈前淋巴结扩散,目前仍在肿瘤科进一步放化疗中。复习相关文献并结合本组病例提示,MCC诊断主要依靠病理检查,彻底切除病灶并结合术后放化疗是其治疗的主要手段,免疫治疗是目前新的发展趋势。
The Merkel cell carcinoma (MCC) is a rare highly malignant primary neuroendocrine carcinoma of the skin, especially in the eyelids. In this report, the clinical history and treatment course of 2 patients with MCC of the eyelid were reviewed and summarized. Patient 1 with primary MCC of eyelid was treated with complete surgical excision, with good results. Follow-up for 7 years had shown no recurrence. Patient 2 with the eyelid relapse in situ two months after resection in another hospital, was treated with complete surgical excision again, but the tumor metastasized to the ipsilateral lymphonodi parotidici and cervical lymph nodes two months after the surgery. The patient is now going through radiotherapy and chemotherapy in oncology department. According to the review of literatures, the diagnosis was based on the pathologic evidence. Complete removal of lesion combined with postoperative radiotherapy and chemotherapy is a major means of treatment for MCC. Immunotherapy will play a more important role in the future.
其他期刊
  • 眼科学报

    主管:中华人民共和国教育部
    主办:中山大学
    承办:中山大学中山眼科中心
    主编:林浩添
    主管:中华人民共和国教育部
    主办:中山大学
    浏览
  • Eye Science

    主管:中华人民共和国教育部
    主办:中山大学
    承办:中山大学中山眼科中心
    主编:林浩添
    主管:中华人民共和国教育部
    主办:中山大学
    浏览
推荐阅读
出版者信息
中山眼科



中山大学